Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced or Metastatic Non-small Cell Lung”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04872634
What this trial is testing

Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment

Who this might be right for
Non-small Cell Lung Cancer
NKMAX Co., Ltd. 24
Large-scale testing (Phase 3)Looking for participantsNCT06956001
What this trial is testing

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

Who this might be right for
EGFRNSCLC (Advanced Non-small Cell Lung Cancer)
Allist Pharmaceuticals, Inc. 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT05445843
What this trial is testing

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Who this might be right for
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Novartis Pharmaceuticals 95
Testing effectiveness (Phase 2)Ended earlyNCT02580708
What this trial is testing

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT02955290
What this trial is testing

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Who this might be right for
Advanced Head and Neck Squamous Cell CarcinomaLung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell Carcinoma+13 more
Roswell Park Cancer Institute 51
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117
What this trial is testing

Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 329
Large-scale testing (Phase 3)Study completedNCT00556712
What this trial is testing

Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 889
Testing effectiveness (Phase 2)Study completedNCT00003989
What this trial is testing

ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma

Who this might be right for
Lung CancerMelanoma (Skin)
European Organisation for Research and Treatment of Cancer - EORTC 50
Early research (Phase 1)Ended earlyNCT04892017
What this trial is testing

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid TumorMetastatic Solid Tumor
Deciphera Pharmaceuticals, LLC 91
Testing effectiveness (Phase 2)Study completedNCT00547105
What this trial is testing

Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
University of Texas Southwestern Medical Center 24
Early research (Phase 1)Looking for participantsNCT04686305
What this trial is testing

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 304
Early research (Phase 1)Enrolling By InvitationNCT07218003
What this trial is testing

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Who this might be right for
Non Small Cell Lung CancerCervical CancerHead and Neck Squamous Cell Cancer+7 more
Rondo Therapeutics 149
Testing effectiveness (Phase 2)Ended earlyNCT04844073
What this trial is testing

TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Who this might be right for
Squamous Cell Cancer of Head and Neck (SCCHN)Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer
Takeda 95
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Large-scale testing (Phase 3)UnknownNCT04033354
What this trial is testing

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Who this might be right for
Squamous Non Small Cell Lung Cancer
Shanghai Henlius Biotech 537
Early research (Phase 1)UnknownNCT03274479
What this trial is testing

PBF-1129 in Patients With NSCLC

Who this might be right for
Locally Advanced or Metastatic NSCLC
Palobiofarma SL 18
Large-scale testing (Phase 3)Study completedNCT03191786
What this trial is testing

Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 453
Early research (Phase 1)WithdrawnNCT06681870
What this trial is testing

ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors

Who this might be right for
CLDN6-positive Solid TumorOvarian CancerEndometrial Cancer+3 more
Astellas Pharma Global Development, Inc.
Early research (Phase 1)Ended earlyNCT03054038
What this trial is testing

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Carcinoma
Vanderbilt-Ingram Cancer Center 22
Testing effectiveness (Phase 2)Study completedNCT01372384
What this trial is testing

Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 6
Next Page